Meldonium manufacturers claim course lasts four to six weeks, not 10 years, after Maria Sharapova case
Sharapova has been legally taking meldonium for the past decade, but a Wada rule change banned the substance at the start of this year
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Latvian company responsible for manufacturing meldonium, the banned performance enhancing drug that Maria Sharapova has tested positive for, have confirmed that a normal course of treatment lasts from four to six weeks.
Sharapova claims to have first used meldonium in 2006 after being prescribed the drug by a family-approved doctor, and continued to use it legally throughout her career. However, the 28-year-old Russian failed to acknowledge that the drug was banned on 1 January 2016, given that the World Anti-Doping Agency [Wada] had discovered "evidence of its use by athletes with the intention of enhancing performance".
The five-time Grand Slam winner announced the news in a Los Angeles press conference on Monday in which she confirmed that she has knowingly taken the substance for the past decade, although she did not clarify how often she consumed meldonium - which is not an approved medication in the United States of America.
Manufacturer's Grindeks, the Latvian company responsible for making meldonium, told the Associated Press in an emailed statement: "Depending on the patient's health condition, treatment course of meldonium preparations may vary from four to six weeks. Treatment course can be repeated twice or thrice a year.
"Only physicians can follow and evaluate patient's health condition and state whether the patient should use meldonium for a longer period of time."
Meldonium is used to improve blood flow in patients suffering from cardiac and vascular diseases, but it has also been found to give healthy athletes a performance boost due to its ability to increase endurance and aerobic capabilities that led to its supposed abuse by sportsmen and sportswomen.
However, Grindeks claimed that the substance can also have a negative impact on a healthy athlete, adding: "It would be reasonable to recommend them to use meldonium as a cell protector to avoid heart failure or muscle damage in case of unwanted overload."
The statement also revealed that meldonium slows down how the body breaks down fatty acids during sports activity, which can have a negative impact on an athlete’s energy levels.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments